Analysis of the current status of the protection in children from of polio

Introduction. There is a risk of an exponential increase in the incidence of polio in the world, if there is a deviation from the current plan of measures to localize endemic areas of polio and until global eradication of the virus achieved. Routine immunization against polio and widespread vaccination is the main goal of the polio control strategy. There is currently no need to strengthen planned vaccination work in Russia to consolidate the results of the polio control program, as evidenced by the data of dynamic serological monitoring. Aim: Evaluate the level of seroconversion after administration of poliovaccine and the duration of protective antibody titer maintenance in children.

Materials and methods. A single-stage, single-center determination of the titer of antibodies to poliovirus types 1 and 3 was carried out using the neutralization method. There were studied 162 samples collected as part of the assignment from the Center of Hygiene and Epidemiology of the Republic of Buryatia (1.44% of the pediatric population of the children’s polyclinic): three groups of 1–2 years, 3–4 years and 15–17 years children. The average age in the group 1 was 1.64 ± 0.48 years, group 2 — 3.48 ± 0.54 years, and group 3 — 15.38 ± 0.67 years. Medical documentation was analyzed and compared: completed preventive vaccination cards (form 063/u) and preventive vaccination sheet in the child development card (form 112/u) for a complete collection children’s vaccination history.

Results. Deviations of vaccination dates from the current national calendar of preventive vaccinations noted in all age groups with a high frequency. In our analysis, 100% of children demonstrate the presence of protective antibodies to poliomyelitis types 1 and 3. The duration of preservation of neutralizing antibodies is 13.05 ± 0.94 years, with an average of 9–15 years.

Conclusion. The analyzed serological monitoring of postvaccinal immunity to poliomyelitis testifies to the high efficiency of the preventive work.

Contribution:
Balzhieva V.V., Khlebnikova L.A. — concept and design of the study;
Khlebnikova L.A. — data collection and processing;
Balzhieva V.V. — statistical processing of the data;
Balzhieva V.V., Khlebnikova L.A. — writing the text; editing the text, approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: August 14, 2024
Accepted: October 08, 2024
Published: November 12, 2024

1. Ciapponi A., Bardach A., Rey Ares L., Glujovsky D., Cafferata M.L., Cesaroni S., et al. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database Syst. Rev. 2019; 12(12): CD011260. https://doi.org/10.1002/14651858.CD011260.pub2

2. Ivanova O.E., Kozlovskaya L.I., Eremeeva T.P., Shakaryan A.K., Ivanov A.P., Baykova O.Y., et al. Vaccine-associated paralytic poliomyelitis in a child: fast transformation from Sabin-like virus to vaccine-derived poliovirus triggered an epidemiological response in two countries of the European region. Int. J. Infect. Dis. 2022; 125: 35–41. https://doi.org/10.1016/j.ijid.2022.09.034

3. Vashishtha V.M., Kumar P. Recurring outbreaks of circulating vaccine-derived Polioviruses: implications for global poliovirus immunization strategy. Indian Pediatr. 2023; 60(6): 437–41.

4. Sáez-Llorens X., Chan M., DeAntonio R., Petersen T., Olesen C., Jensen J.S., et al. Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine. Vaccine. 2022; 40(40): 5835–41. https://doi.org/10.1016/j.vaccine.2022.06.084

5. Mendes A., Whiteman A., Nygren B., Kaplan B., Hussain I., Soofi S., et al. Immunity to poliovirus in Afghanistan: A household sampling method for serological assessment based on geographical information systems. Geospat. Health. 2022; 17(2). https://doi.org/10.4081/gh.2022.1107

6. Soofi S.B., Vadsaria K., Mannan S., Habib M.A., Tabassum F., Hussain I., et al. Factors associated with vaccine refusal (polio and routine immunization) in high-risk areas of Pakistan: a matched case-control study. Vaccines (Basel). 2023; 11(5): 947. https://doi.org/10.3390/vaccines11050947

7. Ashraf M.F., Daim S.U.R., Fayyaz H., Ashraf M.A., Ashraf M. Navigating Pakistan’s immunization landscape: Progress and pitfalls. IJID Reg. 2024; 12: 100382. https://doi.org/10.1016/j.ijregi.2024.100382

8. Ivanova O.E. Polio today: state of the global eradication program and modern strategy of who on immunization. Epidemiologiya i vaktsinoprofilaktika. 2015; 14(2): 73–8. https://elibrary.ru/trsrgh (in Russian)

9. Sáez-Llorens X., Clemens R., Leroux-Roels G., Jimeno J., Clemens S.A., Weldon W.C., et al. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect. Dis. 2016; 16(3): 321–30. https://doi.org/10.1016/S1473-3099(15)00488-0

10. Ishmukhametov A.A., Siniugina А.А., Chumakov K.M. The development of polio vaccines: the current update (review). Sovremennye tekhnologii v meditsine. 2019; 11(4): 200–15. https://doi.org/10.17691/stm2019.11.4.22 https://elibrary.ru/hbsplx (in Russian)

11. Geiger K., Stehling-Ariza T., Bigouette J.P., Bennett S.D., Burns C.C., Quddus A., et al. Progress toward poliomyelitis eradication – worldwide, January 2022 – December 2023. MMWR Morb. Mortal. Wkly Rep. 2024; 73(19): 441–6. https://doi.org/10.15585/mmwr.mm7319a4

12. Zhou F., Jatlaoui T.C., Leidner A.J., Carter R.J., Dong X., Santoli J.M., et al. Health and economic benefits of routine childhood immunizations in the era of the vaccines for children program – United States, 1994–2023. MMWR Morb. Mortal. Wkly Rep. 2024; 73(31): 682–5. https://doi.org/10.15585/mmwr.mm7331a2

13. Belova O.E. To the future without poliomyelitis: the state of the epidemic, vaccination issues (review). Zhivye i biokosnye sistemy. 2019; (28): 6. https://elibrary.ru/sluplg (in Russian)

14. Ivanova O.E., Eremeeva T.P., Baykova O.Y., Krasota A.Y., Yakovchuk E.V., Shustova E.Y., et al. Detection of polioviruses type 2 among migrant children arriving to the Russian Federation from a country with a registered poliomyelitis outbreak. Vaccines (Basel). 2024; 12(7): 718. https://doi.org/10.3390/vaccines12070718

15. Shamsheva O.V. Evolution of the national vaccination calendar. Results and prospects. Detskie infektsii. 2022; 21(1): 5–15. https://doi.org/10.22627/2072-8107-2022-21-1-5-15 https://elibrary.ru/lojsmd (in Russian)

16. Sharma A.K., Verma H., Estivariz C.F., Bajracharaya L., Rai G., Shah G., et al. Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial. Lancet Microbe. 2023; 4(11): e923–30. https://doi.org/10.1016/S2666-5247(23)00215-X

17. Habib M.A., Soofi S.B., Hussain Z., Ahmed I., Tahir R., Anwar S., et al. A holistic strategy of mother and child health care to improve the coverage of routine and polio immunization in Pakistan: results from a demonstration project. Vaccines (Basel). 2024; 12(1): 89. https://doi.org/10.3390/vaccines12010089

18. Soofi S.B., Martinez M., Farag N.H., Hendley W.S., Ehrhardt D., Ahmed I., et al. Poliovirus immunity among children aged 6-11 and 36-48 months in 14 polio high-risk provinces of Afghanistan: A Health-Facility-Based Study. Vaccines (Basel). 2022; 10(10): 1726. https://doi.org/10.3390/vaccines10101726

19. Dalmatov V.V., Vaytovich M.A., Burashnikova I.P., Loginovskikh N.V., Gotval’d R.H., Tumorina S.Z., et al. Serologic monitoring in the system of epidemiologic surveillance of infections controlled by means of immunoprophylaxis. Epidemiologiya i vaktsinoprofilaktika. 2004; 5(18): 16–20. (in Russian)

20. Larocca A.M.V., Bianchi F.P., Bozzi A., Tafuri S., Stefanizzi P., Germinario C.A. Long-term immunogenicity of inactivated and oral polio vaccines: An Italian retrospective cohort study. Vaccines (Basel). 2022; 10(8): 1329. https://doi.org /10.3390/vaccines10081329

21. Quarleri J. Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus. Geroscience. 2023; 45(2): 707–17. https://doi.org/10.1007/s11357-022-00672-7